Ahammune Biosciences
PrivateLast Round
Series A
Sep 25, 2024
Total Funding Raised
$5M
Momentum Score
25 /100
Company Overview
Ahammune Biosciences is a biotechnology company that develops small molecule-based therapeutics for the treatment of skin diseases, with a current focus on the depigmenting disorder, Vitiligo.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ahammune Biosciences Comps
Public and private peers based on sector, stage, and business model.
Ahammune Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Sep 25, 2024 | ||||
| Early Funding | Apr 26, 2021 |
Ahammune Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| IAN Group | Series A, Early Funding |
| pi Ventures | Series A |
| Colossa Ventures | Series A |
| Ideaspring Capital | Series A, Early Funding |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 20, 2026
Monthly visitors increased 4390% MoM.
Ahammune Biosciences Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Ahammune Biosciences's valuation, stock price, and market status.
